Chih-Hsien Wu1, Jiunn-Liang Ko2, Shiuan-Chih Chen3, Yu-Wen Lin1, Chih-Ping Han4, Ti-Yuan Yang5, Ming-Hsien Chien6, Po-Hui Wang7. 1. Institute of Medicine, Chung Shan Medical University, No. 110, Section 1, Chien-Kuo North Road, Taichung 40201, Taiwan. 2. Institute of Medicine, Chung Shan Medical University, No. 110, Section 1, Chien-Kuo North Road, Taichung 40201, Taiwan; Department of Obstetrics and Gynecology, Chung Shan Medical University Hospital, No. 110, Section 1, Chien-Kuo North Road, Taichung 40201, Taiwan. Electronic address: jlko@csmu.edu.tw. 3. School of Medicine, Chung Shan Medical University, Taichung, Taiwan; Department of Family and Community Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan. 4. Department of Obstetrics and Gynecology, Chung Shan Medical University Hospital, No. 110, Section 1, Chien-Kuo North Road, Taichung 40201, Taiwan; School of Medicine, Chung Shan Medical University, Taichung, Taiwan; Department of Pathology, Chung Shan Medical University Hospital, Taichung, Taiwan. 5. School of Medicine, Taipei Medical University, No. 250, Wuxing Street, Xinyi District, Taipei 11042, Taiwan. 6. Laboratory of Molecular and Cellular Toxicology, Institute of Toxicology, College of Medicine and Angiogenesis Research Center, National Taiwan University, No. 1, Section 1, Ren-Ai Road, Taipei 10016, Taiwan; Taipei Medical University and Wang-Fang Hospital, Taipei 116, Taiwan. 7. Institute of Medicine, Chung Shan Medical University, No. 110, Section 1, Chien-Kuo North Road, Taichung 40201, Taiwan; Department of Obstetrics and Gynecology, Chung Shan Medical University Hospital, No. 110, Section 1, Chien-Kuo North Road, Taichung 40201, Taiwan; School of Medicine, Chung Shan Medical University, Taichung, Taiwan. Electronic address: wang84921346@yahoo.com.tw.
Abstract
OBJECTIVE: Over-expression of the aldo-keto reductase family 1 member C3 (AKR1C3) has been demonstrated in many human cancers. Lipocalin 2 (LCN2) is reported to inhibit cervical cancer metastasis but little is known regarding its relationship with AKR1C3 in the development and progression of uterine cervical cancer. This study aimed to investigate the involvement of AKR1C3 and its relationship with LCN2 in cervical cancer. METHODS: The roles of AKR1C3 and LCN2 were investigated using the lentivirus shRNA system in SiHa and Caski cervical cancer cells. LCN2 and matrix metalloproteinase-2 (MMP-2) promoters were constructed to demonstrate transcriptional regulation by shAKR1C3 and shLCN2, respectively. The influences of metastatic phenotypes were analyzed by wound healing, Boyden chamber, and immunofluorescence assays. The activity of MMP-2 was determined by zymography assay. The impacts of AKR1C3 and LCN2 on patient prognosis were evaluated using tissue microarrays by Cox regression and Kaplan-Meier models. RESULTS: Silencing of the AKR1C3 gene increased the expression of LCN2 and decreased the migratory and invasive abilities and changed the cytoskeleton of cervical cancer cells. When AKR1C3 was over-expressed, it decreased LCN2 promoter activity and LCN2 expression and increased cell migration. The mRNA level and enzyme activity of MMP-2 increased in silenced LCN2 cells. Positive AKR1C3 and negative LCN2 were correlated with higher recurrence and poorer survival of cervical cancer patients. CONCLUSIONS: Silencing of AKR1C3 increases LCN2 expression and inhibits metastasis in cervical cancer. Both AKR1C3 and LCN2 serve as molecular targets for cancer therapy to improve the clinical outcome of cervical cancer patients.
OBJECTIVE: Over-expression of the aldo-keto reductase family 1 member C3 (AKR1C3) has been demonstrated in many humancancers. Lipocalin 2 (LCN2) is reported to inhibit cervical cancer metastasis but little is known regarding its relationship with AKR1C3 in the development and progression of uterine cervical cancer. This study aimed to investigate the involvement of AKR1C3 and its relationship with LCN2 in cervical cancer. METHODS: The roles of AKR1C3 and LCN2 were investigated using the lentivirus shRNA system in SiHa and Caski cervical cancer cells. LCN2 and matrix metalloproteinase-2 (MMP-2) promoters were constructed to demonstrate transcriptional regulation by shAKR1C3 and shLCN2, respectively. The influences of metastatic phenotypes were analyzed by wound healing, Boyden chamber, and immunofluorescence assays. The activity of MMP-2 was determined by zymography assay. The impacts of AKR1C3 and LCN2 on patient prognosis were evaluated using tissue microarrays by Cox regression and Kaplan-Meier models. RESULTS: Silencing of the AKR1C3 gene increased the expression of LCN2 and decreased the migratory and invasive abilities and changed the cytoskeleton of cervical cancer cells. When AKR1C3 was over-expressed, it decreased LCN2 promoter activity and LCN2 expression and increased cell migration. The mRNA level and enzyme activity of MMP-2 increased in silenced LCN2 cells. Positive AKR1C3 and negative LCN2 were correlated with higher recurrence and poorer survival of cervical cancerpatients. CONCLUSIONS: Silencing of AKR1C3 increases LCN2 expression and inhibits metastasis in cervical cancer. Both AKR1C3 and LCN2 serve as molecular targets for cancer therapy to improve the clinical outcome of cervical cancerpatients.
Authors: Blanca D López-Ayllón; Javier de Castro-Carpeño; Carlos Rodriguez; Olga Pernía; Inmaculada Ibañez de Cáceres; Cristobal Belda-Iniesta; Rosario Perona; Leandro Sastre Journal: Int J Clin Exp Pathol Date: 2015-03-01
Authors: Johanna Eriksson; Vadim Le Joncour; Pirjo Nummela; Tiina Jahkola; Susanna Virolainen; Pirjo Laakkonen; Olli Saksela; Erkki Hölttä Journal: Oncotarget Date: 2016-03-22
Authors: Chen-Ming Zeng; Lin-Lin Chang; Mei-Dan Ying; Ji Cao; Qiao-Jun He; Hong Zhu; Bo Yang Journal: Front Pharmacol Date: 2017-03-14 Impact factor: 5.810